Medlab Clinical Limited Overview
Medlab Clinical was an Australian clinical-stage biotechnology company. It began as a research-driven, practitioner-only nutraceutical business. From about 2018 to 2022 it repositioned around NanoCelle®, its patented sub-micron delivery platform for oro-buccal, intranasal and transdermal administration. The lead asset was NanaBis™, a 1:1 synthetic CBD and dronabinol buccal spray targeting cancer-induced bone pain as an opioid-sparing therapy. NanaBis was available under Australia's Special Access Scheme and the UK named-patient programme, and was preparing for a multinational Phase III trial. The company sold its Australian nutraceutical business to PharmaCare in November 2021 to fund that pivot. It then attempted a Nasdaq dual listing, which collapsed in January 2023 into a funding crisis. Trading was suspended, most staff were retrenched, the core IP was sold to the founder for a contingent royalty, and the company sought a reverse takeover into strategic minerals. That deal was not completed, and the entity was delisted in February 2025. Today it is a non-operating shell with no disclosed business.
Company's own description (latest disclosures)
The FY2024 Annual Report (lodged 4 Nov 2024) no longer describes an operating business. It states that ASX suspended trading on 27 February 2023. Hall Chadwick was engaged as external consultants for an informal workout. The company retrenched most of its workforce and operated in a care-and-maintenance capacity while the directors devised a corporate restructure. Note 3 (Operating segments) records that, after the nutraceuticals business was discontinued in FY2022, the group had a single segment. The note also says the group "does not have any products/services it derives revenue from" (FY2024 AR, Note 3).
The last full description of an operating business is in the October 2022 F-1. There the company called itself an Australian biotechnology company that develops fixed-dose combinations of the NanoCelle® delivery platform with active pharmaceutical ingredients (APIs). It stated an aim to disrupt the delivery-platform market for pain and mental-health pharmaceuticals, and a revenue strategy built on licensing its IP and assets to large established companies.
Business model and revenue model (historical)
| Model element | FY2015–FY2021 (pre-pivot) | FY2022–FY2023 (pharma pivot) | FY2024 onward (shell) |
|---|---|---|---|
| Primary activity | Practitioner-only nutraceuticals (34 formulations by 2019) plus clinical research | NanoCelle®-based drug development (NanaBis, NanoCBD, MDC2000), real-world evidence under SAS / named-patient access | Care and maintenance; search for a reverse-takeover asset |
| Revenue type | Product sales through pharmacy wholesale (API/Priceline, TerryWhite Chemmart, Symbion), mostly practitioner channel | Product sales of NanaBis/NanoCBD under SAS; royalties and licence fees (PharmaCare, Cultech, YesHealth, American Nutritional Corp) | Residual pharmaceutical sales of A$11,894 in FY2024; contingent 20% royalty to "Entitled Shareholders" from Dr Hall (paid directly to shareholders, not to the company) |
| Product / service / licensing mix | Mostly product | Mixed product plus licensing; licensing was the stated strategic priority | — |
| Non-operating funding | Equity placements; R&D Tax Incentive refunds | R&D Tax Incentive (A$2.87M recognised FY2023); grants | Debt forgiveness (A$0.09M); Hall Chadwick fees accrued against future equity |
Value-chain position
Medlab was an asset-light IP owner and developer. The F-1 states it had no in-house manufacturing and relied on third parties. Those included Renaissance Lakewood LLC (US CDMO, FDA/DEA experienced), Natural Factors (Canada, TGA-approved), Extractas (formerly Tasmanian Alkaloids), and Purisys LLC (Georgia, US) for biosynthetic CBD and dronabinol with FDA Drug Master Files. It did own an OGTR-registered laboratory in Sydney, where NanoCelle was developed, and handled formulation, clinical design, regulatory filings and real-world-evidence collection itself.
Customer types and end-markets
Prescribers and patients: Australian doctors prescribing under the TGA Special Access Scheme; UK prescribers under the MHRA named-patient programme. More than 1,000 Australian patients were under clinical management on NanaBis by 2022 (Stockhead, Q3 FY2022 update), and over 1,200 by July 2022 (Q4 FY2022 4C).
Pharmacy and practitioner channel (until Nov 2021): integrative-medicine practitioners and community pharmacy banner groups.
Licensees and distributors: PharmaCare (Australia/NZ), Cultech (UK), YesHealth (Malaysia/Vietnam/Singapore), American Nutritional Corporation (US, NuScripts private label), Mega Lifesciences (heads of agreement for NanaBis global distribution).
Therapeutic end-markets: cancer-induced bone pain and neuropathic pain, occupational stress and mild chronic pain, major depressive disorder, gut health, diabetes and obesity (exploratory), allergies, and nasal nucleic-acid vaccines (pre-clinical).
Independent characterisation
Medlab was a sub-scale, founder-led micro-cap biotech. It tried to bridge a cash-generating consumer-health business and a capital-hungry regulated-drug pipeline, and ultimately could do neither. The PharmaCare divestment (A$1.6M cash, per the F-1) removed most recurring revenue just as Phase III and FDA costs were set to rise. The company then depended on a single external financing event, the Nasdaq IPO, which failed amid a hostile biotech funding market in late 2022. The platform thesis (NanoCelle sub-micron buccal delivery) had real IP: patents granted in the US, Europe, Australia and other jurisdictions to 2036. But it never produced a registered (approved) prescription medicine, a pivotal efficacy readout, or a licensing deal with a large pharmaceutical company. The entity's endgame, a related-party sale of the IP to the founder for a contingent royalty followed by a failed minerals RTO, is typical of ASX shell outcomes for failed micro-cap biotechs.
Strategy
Stated strategy (pharma era, F-1, October 2022)
The F-1 set out five strategic pillars, paraphrased here:
-
advance the investigational drug candidates toward US and other approvals;
-
use accelerated access routes, including compassionate-use programmes in the US, UK and Australia;
-
develop further clinical products for unmet needs;
-
maintain a strong IP estate in key markets to 2036;
-
expand global availability.
The revenue strategy was explicitly licence-led: partner with large established companies rather than build commercial infrastructure.
Initiatives in the last 24 months of reported activity (Nov 2022 – Feb 2025)
| Date | Initiative | Outcome |
|---|---|---|
| Jun 2022 – Jan 2023 | Nasdaq dual listing (MDLB) to raise about US$7M net (Edison) | Abandoned 20 Jan 2023 |
| Nov 2022 | UK named-patient launch of NanaBis/NanaDol | Import permission obtained; scale not disclosed |
| 2022–2023 | NanaBis Phase III (about 360 patients; US/UK/Australia) and US IND | Never commenced |
| Feb–Mar 2023 | Informal workout with Hall Chadwick; 78% headcount reduction; lease exit | Completed; company placed in care and maintenance |
| May 2023 | 20% reduction in executive hours | Implemented |
| Aug–Nov 2023 | Search for recapitalisation, restructure or asset sale; proposed licence of NanoCelle to an unrelated party plus a capital raising | Licence not completed; replaced by the related-party sale |
| 12 Jan 2024 | Sale of IP and US subsidiaries to Dr Sean Hall for a 20% royalty to Entitled Shareholders over 4 years | Completed |
| 2,024 | Reverse takeover of a strategic-minerals business (net-zero commodities); A$5M raise; quotation expected 3–4 months after a deal | No binding agreement announced; deadline missed |
| 28 Feb 2025 | — | Delisted |
ESG and sustainability commitments: None disclosed. The FY2024 AR states the group was not subject to significant environmental regulation.
Medium-term financial targets and guidance: None issued.
Products & Services
All products below were owned through Medlab IP Pty Ltd or licensed by the group before 12 January 2024. The listed entity no longer owns them. The rights now sit with Dr Sean Hall's interests, subject to the 20% shareholder royalty.
Platform technology
| Product | Description | Key specifications | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|---|
| NanoCelle® | Proprietary sub-micron (nanoparticle) delivery platform | Particles of 1–100 nm; routes include oro-buccal/sublingual spray, intranasal spray, dermal and transdermal, topical, oral gel capsules and liquids, adsorption from solid carriers. Designed to bypass gastrointestinal and first-pass hepatic absorption so lower doses can be used. Over 350,000 doses administered via compassionate use, trials and sales (F-1, Oct 2022). Patented in Australia, Canada, EU/EPC states, Hong Kong, NZ, US and UK, with Singapore pending; protection to 2036 | Pharma licensees, CDMOs, consumer-health partners | Developed in Medlab's OGTR-registered lab; US patent granted Oct 2021 | Licensing and royalty; technology-transfer licences to manufacturers |
Prescription and investigational pharmaceuticals
| Product | Description and indication | Stage (last disclosed) | Regulatory pathway | Key details |
|---|---|---|---|---|
| NanaBis™ (UK: "NanaDol") | 1:1 (50:50) synthetic CBD and dronabinol (synthetic THC) buccal spray via NanoCelle, for cancer-induced bone pain as an opioid-sparing analgesic; potential extension to neuropathic pain | Phase II at an Australian hospital met primary and secondary endpoints (F-1). Phase III planned with about 360 participants in the US, Australia and UK, using a randomised-withdrawal monotherapy design. Edison expected enrolment in Q4 CY2023, which never happened. Real-world dataset of 1,172+ patients | ARTG-registered (F-1); TGA Special Access Scheme; UK named-patient programme (MHRA import permission 25 Nov 2022); US FDA-led programme with API Drug Master File via Purisys | Lead asset. Switched to 100% synthetic APIs during COVID on FDA guidance |
| NanoCBD™ | CBD-only NanoCelle buccal spray for occupational stress and mild chronic pain | PK/PD studies in healthy volunteers planned for mid-2023 (F-1) | TGA-led over-the-counter registered-medicine pathway; MHRA named-patient approval Apr 2022 | Shares DMF, CMC and US manufacturing with NanaBis |
| NanaBidial™ | Cannabinoid formulation for cancer pain (earlier-generation programme) | Development status not updated after c.2018 | ODC export licence covered it | Appears to have been superseded by NanaBis |
| MDC2000 | Single molecule encapsulated in NanoCelle for major depressive disorder | Returned to pre-clinical after a 2020 study closed early due to COVID; clinical restart expected early 2023 (not executed) | Candidate for an FDA 505(b)(2) NDA | — |
| NanoCelle® Nucleic Acid ("Nasal RNA") | Nasal delivery of siRNA and RNA vaccines | Pre-clinical. NanoCelle-insulin nasal adherence studies met endpoints; siRNA encapsulation was the next step | TGA-focused; government-funded collaboration | IP jointly owned one-third each with UNSW and Macquarie University |
| NanoCelle® atorvastatin | Buccal statin for hypercholesterolaemia | Phase 0 planned (c.2018) | Reformulation of an existing molecule | No later disclosure found |
| NanoCelle® insulin | Buccal/nasal insulin for Type II diabetes | Phase 0 planned (c.2018); nasal adherence work completed by 2022 | Reformulation of an existing molecule | — |
Consumer health / nutraceuticals (divested or licensed)
| Product | Description | Status | Licensee / channel |
|---|---|---|---|
| NanoCelle® D3 | Vitamin D3 spray for immunity and bone health; ARTG-listed | Sold OTC through PharmaCare in Australia and as a food supplement in NZ (Medsafe) | PharmaCare (Aus/NZ); American Nutritional Corp (US, NuScripts) |
| NanoCelle® B12 | Vitamin B12 spray to lower homocysteine and support the nervous system; ARTG-listed | As above | As above |
| NRGBiotic™ | Patented probiotic for patients with major depressive disorder; manufactured by Cultech Ltd (UK) | Three-year UK trade deal, with European/US optionality | Cultech Ltd (UK exclusive, US non-exclusive) |
| Practitioner-only nutraceutical range | 34 formulations by 2019, many patent-protected; microbiome-focused research. 29 products transferred to PharmaCare | Australian rights sold to PharmaCare effective 1 Nov 2021; rights outside Australia retained (F-1/A) | PharmaCare (Australia); YesHealth (12 products, Malaysia/Vietnam exclusive, Singapore non-exclusive) |
Product-level pricing was not publicly disclosed for any product. YesHealth supply was on a cost-plus basis plus royalties on net sales (Stockhead).
Financial Narrative
Primary source: the FY2024 Annual Report's five-year summary (FY2020–FY2024) and its audited FY2023/FY2024 statements. FY2020–FY2022 line items beyond revenue and loss come from the Kalkine aggregator, which draws on company filings, and are labelled. FY2025 figures were not publicly disclosed.
Income statement
Notes. (a) The company's 5-year summary and Stockopedia's revenue series diverge for FY2021–FY2022. The difference most likely reflects the restatement of nutraceutical revenue into discontinued operations; both are shown. (b) The Q4 FY2022 Appendix 4C cites "full-year cash operating revenues" of A$6.2M, a cash-receipts measure that includes divestment-related inflows and is not comparable to accounting revenue. (c) Derived FY2023 EBIT = loss before tax (-6.433) + finance costs (0.033) - interest revenue (0.052). FY2023 EBITDA adds back D&A of 0.711. FY2023 gross profit = revenue (0.892) - raw materials (0.090). (d) Kalkine shows FY2022 income before tax of -8.388, against a company after-tax loss of -7.229; the gap is probably discontinued-operations results. The company figure is used. (e) EPS is restated for the 150:1 consolidation.
Margins and growth
Revenue CAGR FY2020–FY2024 (company series): -74.6% a year (derived). Stockopedia reports -71.52% on its own series. Margins use the company revenue series; FY2020–FY2022 gross margin uses the Kalkine gross profit, which may be on a different revenue basis, so treat it as indicative.
Balance sheet
Sources: FY2024 AR statements of financial position, changes in equity (FY2022 = 1 July 2022 opening balances), and the cash-flow note. FY2024 payables include A$920,443 accrued to Hall Chadwick, payable only in shares if the company re-lists. Hall Chadwick has said under a non-binding term sheet that it will not enforce this if no re-listing occurs. Interim data: cash was A$9.75M at 30 Sep 2021 and A$11.22M at 31 Dec 2021 (Kalkine), A$8.6M at 31 Mar 2022 (Stockhead) and A$5.2M at 30 Jun 2022 (Q4 FY2022 4C). Unused Australian tax losses at 30 Jun 2024 were A$31.39M, not recognised; FY2023 also had US$5.67M in the US and £0.22M in the UK.
Ratios
Interest coverage and net debt/EBITDA are not meaningful (negative EBITDA, negligible interest). FY2024 ROE is not meaningful because average equity turned negative. Stockopedia shows trailing ROE of -993.58% and operating margin of -14,833.74%, on unstated periods.
Commentary
Revenue. Revenue peaked at about A$4.4M in FY2021 on the company basis, at the height of the pharmacy nutraceutical rollout that began with the 2019 API/Priceline and TerryWhite agreements. It then fell away in three steps: the November 2021 sale of the Australian nutraceutical business to PharmaCare, the switch to small SAS and named-patient pharmaceutical volumes (A$0.89M in FY2023), and the cessation of operations (A$11,894 in FY2024). At no point did Medlab have a revenue base that covered its cost base.
Losses and the R&D Tax Incentive. Attributable losses narrowed from A$13.4M (FY2020) to A$7.2M (FY2022). That reflected cost control and the shift to an asset-light model, not revenue growth. In FY2023 the R&D Tax Incentive (A$2.87M recognised, A$3.69M received in cash) was the single largest source of funds, larger than product revenue by a factor of about three. That dependence made the business fragile: once R&D spending stopped, the refund disappeared too.
Balance sheet erosion. Equity fell from A$7.75M (1 Jul 2022) to A$1.28M (30 Jun 2023) and then to a deficiency of A$0.85M (30 Jun 2024). FY2024 operating cash outflow was only A$0.17M, but only because the final A$2.74M R&D refund arrived. Cumulative contributed capital of A$66.8M against accumulated losses of A$67.7M means shareholders' entire paid-in capital has been consumed.
Inflection points. Two decisions shaped the outcome. First, the FY2022 divestment of nutraceuticals removed the only recurring revenue. Second, the January 2023 withdrawal of the US$7M net Nasdaq offering (Edison) left a cash runway that, in Edison's estimate, extended only into March 2023. Suspension followed within five weeks.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segments Reported by Period
| Period | Segments reported | Contents |
|---|---|---|
Up to FY2021 | Two: Pharmaceuticals and Nutraceuticals (inferred from the FY2024 AR statement that the Nutraceuticals business was discontinued in FY2022) | Pharmaceuticals: NanaBis, NanoCBD, pipeline. Nutraceuticals: 29–34 practitioner-only formulations including NanoCelle D3 and B12 |
FY2022 restatement | Nutraceuticals reclassified as discontinued after the 1 Nov 2021 PharmaCare sale | Pharmaceuticals became the continuing segment |
FY2023–FY2024 | One segment | FY2024 AR Note 3 states there are no products or services generating revenue |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Pharmaceuticals revenue (AUD Mn, company AR) | — | 0.892 | 0.012 |
Nutraceuticals revenue (AUD Mn, discontinued) | — | 0 | 0 |
Pharmaceuticals % of total revenue | 100 | 100 | 100 |
Pharmaceuticals revenue YoY growth (%) | — | — | -98.7 |
Group Entities
| Entity | Country | FY2023 ownership (%) | FY2024 ownership (%) | Status |
|---|---|---|---|---|
Medlab Clinical Limited | Australia | Parent | Parent | Delisted 28 Feb 2025; legal status after delisting not disclosed |
Medlab Pty Ltd | Australia | 100 | 100 | Only remaining subsidiary at 30 Jun 2024 |
Medlab IP Pty Ltd | Australia | 100 | 0 | Sold to Dr Sean Hall, 12 Jan 2024 |
Medlab Clinical US Inc | USA | 100 | 0 | Sold to Dr Sean Hall, 12 Jan 2024 |
Medlab Research Pty Ltd | Australia | 100 | 0 | Deregistered FY2024 |
Medlab Nutraceuticals Inc | USA | 60 | 0 | Deregistered FY2024 (source of the non-controlling interest) |
Medlab Research Ltd | UK | 100 | 0 | Deregistered Jan 2024 |
MDC Europe Ltd | Malta | 100 | 0 | Deregistered FY2024 |
Income Statement and Per-Share Data
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Revenue, company 5-yr summary (AUD Mn) | 2.848 | 4.399 | 3.804 | 0.892 | 0.012 |
Revenue, aggregator continuing-ops basis (AUD Mn, Stockopedia) | 2.92 | 0.76 | 1.33 | 0.94 | 0.01 |
Other income incl. R&D tax incentive (AUD Mn) | — | — | — | 3.462 | 0.127 |
Gross profit (AUD Mn; FY20–22 Kalkine; FY23 derived) | 0.04 | 1.46 | 0.95 | 0.802 | — |
EBIT (AUD Mn; FY20–22 Kalkine; FY23–24 derived) | -13.291 | -12.346 | -8.344 | -6.452 | -2.133 |
EBITDA (AUD Mn; FY20–22 Kalkine; FY23–24 derived) | -12.330 | -11.472 | -7.492 | -5.741 | -2.133 |
Depreciation and amortisation (AUD Mn) | 0.96 | 0.87 | 0.85 | 0.711 | 0 |
Pre-tax income (AUD Mn) | -13.488 | -12.403 | -7.229 | -6.433 | -2.131 |
Net income after tax, total (AUD Mn) | -13.488 | -12.403 | -7.229 | -6.433 | -2.131 |
Net income attributable to owners (AUD Mn) | -13.399 | -12.324 | -7.162 | -6.778 | -2.131 |
Basic EPS (A$ cents, consolidation-adjusted) | -891 | -627 | -314 | -297 | -93 |
Diluted EPS (A$ cents) | -891 | -627 | -314 | -297 | -93 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Gross margin (%) | 1 | 33 | 25 | 90 | — |
EBITDA margin (%) | -433 | -261 | -197 | -644 | -17,933 |
Operating (EBIT) margin (%) | -467 | -281 | -219 | -723 | -17,924 |
Net margin, attributable (%) | -470 | -280 | -188 | -760 | -17,914 |
Revenue YoY growth (%, company series) | — | 54.5 | -13.5 | -76.5 | -98.7 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Cash and equivalents (AUD Mn) | 5.191 | 0.226 | 0.110 |
Trade and other receivables (AUD Mn) | — | 2.868 | 0.001 |
of which R&D tax incentive receivable (AUD Mn) | — | 2.735 | 0 |
Total current assets (AUD Mn) | — | 3.094 | 0.111 |
Total assets (AUD Mn) | — | 3.144 | 0.111 |
Total current liabilities (AUD Mn) | — | 1.851 | 0.962 |
Total liabilities (AUD Mn) | — | 1.864 | 0.962 |
Short-term borrowings (AUD Mn) | 0 | 0 | 0 |
Long-term borrowings (AUD Mn) | 0 | 0 | 0 |
Lease liabilities (AUD Mn) | 1.123 | 0 | 0 |
Net debt incl. leases (AUD Mn; negative = net cash) | -4.068 | -0.226 | -0.110 |
Total equity (AUD Mn) | 7.749 | 1.280 | -0.851 |
Issued capital (AUD Mn) | 66.811 | 66.811 | 66.811 |
Accumulated losses (AUD Mn) | -59.529 | -65.648 | -67.662 |
Goodwill and intangibles (AUD Mn) | — | 0 | 0 |
Working capital (AUD Mn) | — | 1.244 | -0.851 |
NTA per share (A$ cents) | — | 56.06 | -37.26 |
Cash Flow
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | — | — | -5.470 | -0.166 |
of which R&D tax incentive and grant receipts (AUD Mn) | — | — | — | 3.692 | 2.735 |
Capex (AUD Mn) | — | — | — | 0.016 | 0 |
Free cash flow (AUD Mn, derived) | — | — | — | -5.486 | -0.166 |
Divestment proceeds, deferred consideration (AUD Mn) | — | — | — | 0.471 | 0 |
Lease principal repaid (AUD Mn) | — | — | — | 0.482 | 0 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Equity raised (AUD Mn) | — | — | — | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
ROE (%, attributable loss / average equity) | — | -150 | — |
ROA (%, loss / closing assets) | — | -216 | -1,913 |
Current ratio (x) | — | 1.67 | 0.12 |
Debt / equity (x, incl. leases) | 0.14 | 0 | 0 |
Asset turnover (x, revenue / closing assets) | — | 0.28 | 0.11 |
Revenue by Region
| Region | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Total group revenue (AUD Mn) | 3.804 | 0.892 | 0.012 |
Region Assets & Liabilities and Revenue by Region
| Indicator | FY2023 |
|---|---|
Foreign-currency liabilities, USD (AUD Mn) | 0.766 |
Foreign-currency liabilities, GBP (AUD Mn) | 0.002 |
Realised FX gain (AUD Mn) | 0.568 |
Per-Share Data and Share Price
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
FY-end share price, pre-consolidation (A$ cents) | 15 | 15 | 5 | — | — |
FY-end share price, consolidation-adjusted (A$, derived ×149.85) | 22.48 | 22.48 | 7.49 | 6.60 | 6.60 |
Shares on issue, post-consolidation basis (M) | — | — | 2.284 | 2.284 | 2.284 |
Return metric
| Return metric | Value |
|---|---|
1-year (to Oct 2026) | n/m: no trading since 27 Feb 2023; delisted |
3-year | n/m |
5-year (Oct 2021 – last trade, approx.) | Strongly negative. The price fell from about 15c pre-consolidation (about A$22.48 adjusted) at June 2021 to A$6.60, roughly -71% (derived), before accounting for loss of liquidity on delisting |
Relative performance (Stockopedia, date unstated) | Underperformed the ASX All Ordinaries by 67.48% over one year and by 50.82% over six months |
Valuation Multiples
| Multiple | Medlab (FY2023 basis) | Medlab (FY2024 basis) |
|---|---|---|
P/E | n/m (loss) | n/m (loss) |
EV/EBITDA | n/m (negative EBITDA) | n/m |
EV/Sales (x) | 16.6 | n/m |
P/B (x) | 11.8 | n/m (negative equity) |
Source Details
| Source | Date | View |
|---|---|---|
Edison Investment Research (issuer-sponsored) | Dec 2022 | Nasdaq listing on track for Q1 CY2023; NanaBis the key catalyst |
Edison Investment Research | Jan 2023 | NanaBis probability of success cut from 45% to 35%; cash runway into March 2023; equity raise likely dilutive |
Market Index | 2024–2025 | Not covered by a major broker |
Consensus estimates | — | None. A Stockopedia "2025E revenue A$6.8M" entry is stale and unreliable, given the FY2024 actual of A$0.012M |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | Never paid (FY2020–FY2024 AR) |
Dividend policy | No intention to pay in the foreseeable future (F-1) |
Buyback authorisations | None (FY2024 AR, Note 11) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | No borrowings. Trade payables of A$962,261 due within one year, of which A$920,443 is the Hall Chadwick accrual, settleable only in shares on re-listing |
Capital history | A$66.81M contributed capital, including the A$24M placement (Jan 2018) and an A$15M placement (date not confirmed) |
Analyst Conclusions
Management guidance
None. The last forward-looking statement (FY2024 AR, 4 Nov 2024) was that the directors were in advanced negotiations to acquire a strategic-minerals business, funded by a A$5M raise and taking about 3–4 months to quotation. No binding agreement was announced before the 27 Feb 2025 deadline, and the entity was delisted.
Consensus expectations
None. There is no broker coverage, no quotation and no published estimates.
Bull case (for residual stakeholders)
-
Royalty optionality. Entitled Shareholders hold a 20% royalty to about January 2028 on NanoCelle IP that is patented to 2036 across major markets. Any licence or commercial launch by Dr Hall's vehicle would flow partly to them, at no cost to the shell.
-
Shell plus tax losses. A$31.39M of Australian tax losses, no debt and a contingent-only adviser liability make a small unlisted shell potentially attractive for a back-door listing or a merger, if the ownership tests can be met.
-
Directors able to source deals. A board with resources-finance and structured-finance networks (Hudson, Walker, Tan) is positioned to find a transaction; a renewed minerals RTO with a fresh admission to the ASX remains theoretically possible.
Bear case
-
Equity has no economic value. Net liabilities of A$0.85M, cash of A$0.11M and no business at 30 June 2024; delisting removes liquidity and disclosure obligations.
-
Royalty value is uncertain and hard to enforce. It is owed by a related private party, there is no public reporting of receipts, NanaBis Phase III never began, and US scheduling constraints persist.
-
Execution track record. Repeated failures (Nasdaq IPO, NanoCelle licence, minerals RTO) and lapses in governance compliance argue against a successful recapitalisation.
Catalysts and monitorables (next 12 months)
-
Any ASIC filings showing a change of status (deregistration, administration or liquidation) for Medlab Clinical Limited.
-
Any announcement of a new ASX admission or reverse takeover involving the entity.
-
Royalty statements or payments to Entitled Shareholders from Dr Hall or his associated entity.
-
Public commercialisation activity on NanaBis or NanoCelle by the private successor: licences, FDA IND or Phase III starts, UK named-patient expansion.
-
Release of FY2025 or FY2026 financial statements, if any are lodged with ASIC.
-
Whether Hall Chadwick converts or waives its A$920k accrued fees.
Analyst verdict
Medlab Clinical Limited is no longer an investable listed company. It is a delisted, non-operating Australian shell. Its last audited balance sheet (30 June 2024) showed A$111k of assets, A$962k of liabilities and A$67.7M of accumulated losses, which exceed every dollar shareholders contributed over the company's life. FY2025 accounts have not been publicly disclosed. Since removal from the ASX on 28 February 2025, no further corporate disclosure has been found.
The failure has three identifiable causes. First, strategic sequencing. Management divested the only revenue-generating business, practitioner nutraceuticals, for A$1.6M in November 2021, before securing the capital needed for a US Phase III programme in cannabinoid analgesia. Second, single-point financing risk. Funding the next stage depended almost entirely on a roughly US$7M Nasdaq IPO, launched into the weakest micro-cap biotech market in a decade; when it was shelved in January 2023, the cash runway ended within weeks. Third, structural difficulty in the asset. NanaBis competed for regulatory and commercial attention with an already approved THC:CBD oromucosal spray, and faced Schedule I complexity in the US. Its evidence base was largely real-world data from Special Access Scheme patients rather than controlled trials.
The workout delivered what remained of the scientific value through a related-party sale of the IP to the founder. The consideration was a four-year, 20% royalty paid directly to shareholders on the register at settlement. Any residual economic value for former MDC holders now sits mostly in that royalty, not in the shell. The shell's potential value lies in its tax losses and shareholder register, both contingent on a transaction that has not materialised.
Verdict: No investment case for the entity. For former shareholders, the only practical asset is a contingent royalty claim. They should verify their Entitled Shareholder status and seek a copy of the 12 January 2024 sale agreement. Monitor ASIC records for status changes.
Principal sources consulted
-
Medlab Clinical Limited, Appendix 4E and Annual Report for the year ended 30 June 2024 (ASX, 4 Nov 2024): financial statements, notes 1–24, Remuneration Report, shareholder information, corporate directory.
-
Medlab Clinical Ltd., SEC Form F-1 (13 Oct 2022) and Forms F-1/A and DRS (2022), CIK 1940322.
-
ASX announcement indexes (InvestSMART, Market Index, TipRanks): suspension, long-term suspension notices, removal from the Official List (28 Feb 2025), results of meetings (14 Feb 2025).
-
Medlab ASX releases: Appendix 4C Q4 FY2022 (29 Jul 2022); EPO Notice of Intention to Grant; ASX aware letter.
-
Edison Investment Research notes on Medlab (2021–2023).
-
GlobeNewswire (4 Nov 2021) on the US NanoCelle patent grant.
-
Trade press: Pharmacy Daily (2018, 2019, 2021), Retail Pharmacy Magazine (2021), Biotech Dispatch, NutraIngredients-Asia (2019), Stockhead (2021–2022), Smallcaps, Kalkine (2022), Drug Target Review, The Greenfields newsletter (2023).
-
Aggregators, used for secondary data only and labelled: Kalkine, Stockopedia, IBISWorld, Pearler.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure | Background | Shareholding |
|---|---|---|---|---|
Matthew Hudson | Non-Executive Chairman | Director from 6 Mar 2023; Chair from 25 Mar 2024 | BCom. Former Credit Suisse and Arthur Andersen adviser; co-founder and MD of Hudson Koch Energy (43 oil and gas wells in Kansas and Oklahoma); founder and MD of United Minerals (historic Potosi Mine, Chihuahua, Mexico) | Nil |
Edmond Tan | Non-Executive Director | From 25 Mar 2024 | BCom. 10+ years in private wealth, family office and structured finance; director of Regenerate Pty Ltd (rare-earth magnet recycling, Houston); Australian representative of Obsidian Global Partners LLC, a structured financier for ASX-listed companies | Nil |
Tim Walker | Non-Executive Director | From 25 Mar 2024 | BCom. Resources corporate finance; M&A in Canada and Australia; past exploration directorships covering lithium, rare earths/niobium, iron ore and base metals | Nil |
Kerem Kaya | CFO, Company Secretary and COO (consultant since 1 Sep 2023) | Employee from 13 May 2021; terminated 31 Aug 2023; re-engaged at A$4,750 a month | BCom, CPA; previously at Novartis | Nil (options expired 24 Jun 2024) |
Board of Directors
| Name | Role | Tenure end | Background |
|---|---|---|---|
Dr Sean Hall | Founder; MD and CEO; Executive Chairman | Resigned 25 Mar 2024 | MD, MBA (Clinical Pharmaceutical Marketing). Over 20 years in Australian healthcare and food industries; built the BioCeuticals practitioner brand; Harvard executive and continuing medical education. Born 1970 (Kalkine) |
Michael Hall | Non-Executive Chairman | Resigned 6 Mar 2023 | Former Head Office Controller at Grace Brothers; chairman of Quantum Health Group |
Drew Townsend | Non-Executive Director | Resigned 26 Feb 2023 | Former senior partner at Hall Chadwick |
Cheryl Maley | Non-Executive Director | 18 Oct 2021 – 26 Feb 2023 | Pharmaceutical executive with US (Chicago) and Asia (Philippines) postings; oncology regulatory experience |
Laurence McAllister | Non-Executive Director | Resigned 31 Aug 2022 | Not detailed |
Mohit Gupta | Non-Executive Director | 8 Aug 2022 – 13 Mar 2023 | Not detailed |
Michael Carter | Non-Executive Director | 13 Mar 2023 – 25 Mar 2024 | BCom (UWA), GradDipAppFin. Stockbroker since 1999; associate director of CPS Capital Group; NED of European Lithium Ltd |
Jeremy Henson | Director of Medical Research | 19 Jul 2022 – 2 Mar 2023 (redundant) | — |
Luis Vitetta | Executive (research) | Resigned 20 Jul 2022 | — |
Ian Curtinsmith | Executive | Redundant 2 Mar 2023 | — |
David Rutolo | Executive | Redundant 30 Jun 2023 | — |
Alan Dworkin | CFO (c.2019) | Before 2021 | Cited in 2019 investor briefings |
Directors' Remuneration
| Person | Year | Salary / fees | Bonus | Superannuation | Long-service leave | Termination | Total |
|---|---|---|---|---|---|---|---|
Sean Hall | FY2024 | 58,846 | 0 | 6,473 | 80,434 | 281,972 | 427,725 |
Sean Hall | FY2023 | 415,192 | 0 | 43,595 | 7,079 | 0 | 465,866 |
Kerem Kaya | FY2024 | 35,813 | 0 | 5,529 | 0 | 86,731 | 128,073 |
Kerem Kaya | FY2023 | 250,447 | 0 | 26,285 | 0 | 0 | 276,732 |
Matthew Hudson | FY2024 | 65,000 | 0 | 0 | 0 | 0 | 65,000 |
Matthew Hudson | FY2023 | 20,000 | 0 | 0 | 0 | 0 | 20,000 |
Michael Carter | FY2024 | 49,725 | 0 | 0 | 0 | 0 | 49,725 |
Michael Hall | FY2023 | 115,385 | 0 | 6,865 | 0 | 0 | 122,250 |
Cheryl Maley | FY2023 | 44,200 | 0 | 0 | 0 | 0 | 44,200 |
Mohit Gupta | FY2023 | 39,826 | 0 | 0 | 0 | 0 | 39,826 |
Ian Curtinsmith | FY2023 | 181,570 | 30,000 | 18,161 | 0 | 27,596 | 257,327 |
Jeremy Henson | FY2023 | 196,071 | 0 | 19,128 | 0 | 38,501 | 253,700 |
David Rutolo | FY2023 | 178,244 | 0 | 13,636 | 0 | 0 | 191,880 |
Total KMP | FY2024 | 209,384 | 0 | 12,002 | 80,434 | 368,703 | 670,523 |
Total KMP | FY2023 | 1,540,617 | 30,000 | 129,232 | 7,079 | 66,097 | 1,773,025 |
Major Shareholders
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | Mr Sean Michael Hall | 389,041 | 17.04 |
| 2 | Farjoy Pty Ltd | 205,663 | 9.01 |
| 3 | HSBC Custody Nominees (Australia) Ltd | 88,229 | 3.86 |
| 4 | UBS Nominees Pty Ltd | 85,316 | 3.74 |
| 5 | FIT Investments Pty Ltd (Hallab Investment A/C) | 75,563 | 3.31 |
| 6 | Realm Group Pty Ltd | 54,705 | 2.40 |
| 7 | Citicorp Nominees Pty Ltd | 49,798 | 2.18 |
| 8 | Mr Drew Anthony Townsend (Townsend Family A/C) | 37,038 | 1.62 |
| 9 | Richard Albarran (Albarran Family No 2 A/C) | 37,038 | 1.62 |
| 10 | United Trolley Collections P/L | 32,970 | 1.44 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Relevance |
|---|---|---|
Cannabinoid prescription medicines | Jazz Pharmaceuticals (Nasdaq: JAZZ; acquired GW Pharmaceuticals 2021) | Owner of Epidiolex and Sativex (nabiximols, a THC:CBD oromucosal spray), the closest approved analogue to NanaBis |
Cannabinoid prescription medicines | Zelira Therapeutics (ASX: ZLD) | Cannabinoid drug developer (pain and insomnia) |
Cannabinoid prescription medicines | Incannex Healthcare (Nasdaq: IXHL; formerly ASX) | Cannabinoid combination drugs; redomiciled to the US |
Cannabinoid prescription medicines | Emyria (ASX: EMD) | Real-world-evidence-led cannabinoid and MDMA programmes |
Cannabinoid OTC / CBD | Bod Science (ASX: BDA; formerly Bod Australia) | Low-dose CBD (MediCabilis/CBD-based OTC) |
Medicinal cannabis supply and SAS | Cann Group (ASX: CAN) | Former partner; supplies SAS and Authorised Prescriber markets |
Medicinal cannabis distribution | Vitura Health (ASX: VIT; formerly Cannatrek/Doctors on Demand group) | Digital clinics and distribution in the Australian SAS market |
Novel delivery / enhanced bioavailability | Avecho Biotechnology (ASX: AVE) | TPM delivery platform with a CBD programme |
Buccal / transmucosal delivery | Aquestive Therapeutics (Nasdaq: AQST) | PharmFilm buccal and sublingual film platform |
Buccal opioid / pain delivery | Collegium Pharmaceutical (Nasdaq: COLL; acquired BioDelivery Sciences 2022) | BEMA buccal delivery in pain |
Practitioner nutraceuticals (historical) | BioCeuticals (Blackmores Group, now part of Kirin) | Practitioner channel leader that Sean Hall had built |
Practitioner nutraceuticals (historical) | PharmaCare, Metagenics | Practitioner/pharmacy supplement competitors (PharmaCare later the acquirer) |
Peer Comparison FY2024
| Metric | Medlab Clinical (FY2024) | Medlab Clinical (FY2023) |
|---|---|---|
Revenue | A$0.012M | A$0.892M |
Revenue growth | -98.7% | -76.5% |
Net margin | n/m | -760% |
R&D intensity | 0% | 137% (reported line only) |
Recent Developments
The 18 months before today (Apr 2025 – Oct 2026) contain no disclosed developments: the entity was delisted on 28 Feb 2025, and no later public announcements were found. The register therefore covers the last 30 months of disclosure (Aug 2022 – Feb 2025).*



